Mutual Alleges Mucinex Monopoly In Extended-Release Guaifenesin
This article was originally published in The Tan Sheet
Mutual Pharmaceutical alleges in an antitrust suit that RB attempts to monopolize the extended-release guaifenesin OTC category with its Mucinex product. The suit says Mutual has lost “tens of millions” due to RB's failure to honor a contract to supply an “authorized generic” of the product.
You may also be interested in...
Perrigo Sets Generic Mucinex Launch After Patent Claim Decision
The private labeler clears a Reckitt Benckiser legal hurdle and will launch generic Mucinex (guaifenesin) by April. Watson has filed ANDAs for three Mucinex products and could be a good strategic partner for Perrigo, an analyst suggests.
Adams Reinforces Mucinex Patents In Settlement Agreement With Mutual
A settlement agreement granting United Research Labs/Mutual Pharmaceuticals a conditional license for certain guaifenesin products could help Adams Respiratory Therapeutics fend off other potential generic competition for its Mucinex brand
L’Oreal Joins Heavyweights Tackling Sustainable Surfactants With Geno Biotech
L’Oreal, Kao and Unilever have partnered with Genomatica, Inc. (Geno) to develop sustainable surfactants by replacing feedstocks such as palm oil and fossil fuels with biotech alternatives.